Avelumab and Radiation in Muscle-Invasive Bladder Cancer
Status:
Active, not recruiting
Trial end date:
2031-01-31
Target enrollment:
Participant gender:
Summary
This research study is studying the effects of adding a certain type of immunotherapy to
standard bladder-directed radiation as a treatment for muscle-invasive urothelial carcinoma
of the bladder.
The drug in this study is: Avelumab (also known as BAVENCIO®)